
Brickell Biotech BBI
Annual report 2023
added 03-15-2024
Brickell Biotech Interest Expense 2011-2026 | BBI
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Brickell Biotech
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 K | 9 K | 69 K | - | 2.1 M | 1.09 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.1 M | 5 K | 654 K |
Quarterly Interest Expense Brickell Biotech
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 2 K | 3 K | - | - | 2 K | 4 K | - | 1 K | 30 K | 34 K | - | - | - | - | - | 1.1 M | 660 K | 224 K | - | 267 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.1 M | 1 K | 211 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Alector
ALEC
|
13.2 M | $ 2.11 | -13.17 % | $ 217 M | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
Apellis Pharmaceuticals
APLS
|
-133 K | $ 20.52 | -2.12 % | $ 2.59 B | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
Axsome Therapeutics
AXSM
|
-15.9 M | $ 164.13 | 0.15 % | $ 8.17 B | ||
|
AgeX Therapeutics
AGE
|
4.9 M | - | -10.17 % | $ 12.2 K | ||
|
Aytu BioScience
AYTU
|
-512 K | $ 2.49 | -3.11 % | $ 15.6 M | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
BridgeBio Pharma
BBIO
|
43.1 M | $ 64.24 | -3.37 % | $ 12.3 B | ||
|
BioAtla
BCAB
|
6.22 M | $ 0.18 | -26.92 % | $ 8.6 M | ||
|
BioCardia
BCDA
|
3 K | $ 1.37 | 6.2 % | $ 29 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
59.3 M | $ 8.61 | -1.66 % | $ 1.78 B | ||
|
Black Diamond Therapeutics
BDTX
|
6.92 M | $ 2.4 | -3.04 % | $ 132 M | ||
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-7.26 M | $ 11.47 | -0.43 % | $ 742 M | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Biogen
BIIB
|
268 M | $ 187.68 | -2.16 % | $ 27.5 B | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
BioVie
BIVI
|
4.3 M | $ 1.38 | -0.01 % | $ 2.04 M | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M | ||
|
Aileron Therapeutics
ALRN
|
685 K | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
1.19 M | - | 4.14 % | $ 49.1 M | ||
|
BioLineRx Ltd.
BLRX
|
9.07 M | $ 2.91 | 2.83 % | $ 908 M | ||
|
Alpine Immune Sciences
ALPN
|
476 K | - | - | $ 2.17 B | ||
|
BioMarin Pharmaceutical
BMRN
|
15.3 M | $ 60.68 | -1.7 % | $ 11.6 B | ||
|
Bristol-Myers Squibb Company
BMY
|
-674 M | $ 62.54 | 0.27 % | $ 127 B | ||
|
Benitec Biopharma
BNTC
|
-126 K | $ 10.85 | -0.5 % | $ 447 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
Aravive
ARAV
|
2.84 M | - | -13.39 % | $ 1.45 M | ||
|
BioXcel Therapeutics
BTAI
|
20.2 M | $ 1.63 | -2.69 % | $ 4.13 M | ||
|
Aptinyx
APTX
|
737 K | - | -39.0 % | $ 4.57 M | ||
|
Athira Pharma
ATHA
|
3.96 M | - | - | $ 269 M |